{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T15:59:50Z","timestamp":1648655990516},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Obwohl Botulinumtoxin\u2011A (BoNT-A) von Leitlinien als First-line-Therapie der fokalen zervikalen Dystonie (ZD) empfohlen wird, existieren kaum Langzeitdaten zu den Behandlungsmodalit\u00e4ten in der klinischen Routine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>Die vorliegende Subgruppenanalyse untersuchte Patientenzufriedenheit und Symptomkontrolle unter Ber\u00fccksichtigung von Behandlungsmodalit\u00e4ten der BoNT-A-Therapie zwischen ZD-Patienten in Deutschland und \u00d6sterreich (DE\/AT, <jats:italic>n<\/jats:italic>\u202f=\u200979) und der internationalen Gesamtkohorte (<jats:italic>n<\/jats:italic>\u202f=\u2009995).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>INTEREST-IN-CD2 war eine prospektive, multizentrische, longitudinale Beobachtungsstudie, die \u00fcber 3\u00a0Jahre der Therapie erwachsener Patienten mit idiopathischer ZD unter BoNT-A-Behandlung folgte. Prim\u00e4rer Endpunkt war die Patientenzufriedenheit mit der Therapie gemessen an der maximalen Zufriedenheit zwischen 2\u00a0Injektionen und der Zufriedenheit zum Zeitpunkt der Reinjektion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die Therapiezufriedenheit im Wirkmaximum war in beiden Populationen im Studienverlauf stabil und vergleichbar gut (82,3\u201392,7\u202f% bzw. 85,0\u201389,9\u202f%). Mit nachlassender BoNT-A-Wirkung zum Ende des Behandlungsintervalls sank die Zufriedenheit ab: Zu Studienbeginn in beiden Gruppen \u00e4hnlich (54,2\u202f% vs. 51,4\u202f%), fiel sie numerisch in der der DE\/AT-Gruppe bis auf 32,7\u202f% ab, blieb dagegen in der Gesamtpopulation stabil. Die Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS)- und Tsui-Scores zeigten keine wesentlichen Unterschiede zwischen der DE\/AT-Gruppe und der Gesamtpopulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerungen<\/jats:title>\n                <jats:p>Die Studie best\u00e4tigt insgesamt eine gute klinische Symptomkontrolle durch BoNT\u2011A. Die im Vergleich von DE\/AT zur internationalen Gesamtkohorte gesehenen numerischen Unterschiede in der aktuellen Zufriedenheit sind m\u00f6glicherweise bedingt durch abweichende Anteile BoNT-A-naiver Patienten beider Gruppen, da diese unterschiedliche Zufriedenheit als vorbehandelte Patienten \u00e4u\u00dferten.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00115-021-01120-1","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T22:33:52Z","timestamp":1620081232000},"page":"1268-1275","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Behandlungszufriedenheit bei Patienten mit zervikaler Dystonie"],"prefix":"10.1007","volume":"92","author":[{"given":"Chi Wang","family":"Ip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Zaragatski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Sycha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"9","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2014.925462","volume":"17","author":"D Bensmail","year":"2014","unstructured":"Bensmail\u00a0D et al (2014) Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J\u00a0Med Econ 17(9):618\u2013625","journal-title":"J Med Econ"},{"issue":"12","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s00415-019-09527-2","volume":"266","author":"C Colosimo","year":"2019","unstructured":"Colosimo\u00a0C, INTEREST IN CD2 study group, study group (2019) How satisfied are cervical dystonia patients after 3\u00a0years of botulinum toxin type A treatment? Results from a\u00a0prospective, long-term observational study. J\u00a0Neurol 266(12):3038\u20133046","journal-title":"J Neurol"},{"key":"1120_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-021-01120-1","author":"C Colosimo","year":"2020","unstructured":"Colosimo C et al (2020) Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: findings from a\u00a0prospective, observational study. J\u00a0Neurol Sci 117015. https:\/\/doi.org\/10.1007\/s00115-021-01120-1","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"1120_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00415-014-7586-2","volume":"262","author":"C Comella","year":"2015","unstructured":"Comella\u00a0C, Bhatia\u00a0K (2015) An international survey of patients with cervical dystonia. J\u00a0Neurol 262(4):837\u2013848","journal-title":"J Neurol"},{"key":"1120_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-021-01120-1","author":"C Comella","year":"2020","unstructured":"Comella C et\u00a0al (2020) Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J\u00a0Neurol. https:\/\/doi.org\/10.1007\/s00115-021-01120-1","journal-title":"J Neurol"},{"key":"1120_CR6","volume-title":"Therapeutics of Parkinson\u2019s disease and other movement disorders","year":"2008","unstructured":"Hallett\u00a0M, Poewe\u00a0W (Hrsg) (2008) Therapeutics of Parkinson\u2019s disease and other movement disorders. John Wiley & Sons,"},{"issue":"10","key":"1120_CR7","doi-asserted-by":"publisher","first-page":"e017902","DOI":"10.1136\/bmjopen-2017-017902","volume":"7","author":"G Irving","year":"2017","unstructured":"Irving\u00a0G et\u00a0al (2017) International variations in primary care physician consultation time: a\u00a0systematic review of 67\u00a0countries. BMJ Open 7(10):e17902","journal-title":"BMJ Open"},{"issue":"8","key":"1120_CR8","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00415-019-09349-2","volume":"266","author":"A Jochim","year":"2019","unstructured":"Jochim\u00a0A et al (2019) Treatment of cervical dystonia with abo-and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. J\u00a0Neurol 266(8):1879\u20131886","journal-title":"J Neurol"},{"key":"1120_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2019.02.017","volume":"399","author":"WH Jost","year":"2019","unstructured":"Jost\u00a0WH et al (2019) Effectiveness of botulinum neurotoxin type A injections in na\u00efve and previously-treated patients suffering from Torti-or Laterocollis or-caput: results from a\u00a0German-Austrian open-label prospective post-marketing surveillance study. J Neurol Sci 399:44\u201350","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"1120_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00415-017-8698-2","volume":"265","author":"VP Misra","year":"2018","unstructured":"Misra\u00a0VP, INTEREST IN CD2 study group, study group (2018) INTEREST IN CD2, a\u00a0global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. J\u00a0Neurol 265(2):402\u2013409","journal-title":"J Neurol"},{"issue":"7","key":"1120_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00415-002-0733-1","volume":"249","author":"J M\u00fcller","year":"2002","unstructured":"M\u00fcller\u00a0J et al (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J\u00a0Neurol 249(7):842\u2013846","journal-title":"J Neurol"},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/PPA.S106560","volume":"10","author":"M Poliziani","year":"2016","unstructured":"Poliziani\u00a0M et\u00a0al (2016) Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. PPA 10:1601","journal-title":"PPA"},{"issue":"1","key":"1120_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.baga.2011.01.001","volume":"1","author":"G Reichel","year":"2011","unstructured":"Reichel\u00a0G (2011) Cervical dystonia: a\u00a0new phenomenological classification for botulinum toxin therapy. Bas Gang 1(1):5\u201312","journal-title":"Bas Gang"},{"issue":"10","key":"1120_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00702-014-1356-2","volume":"122","author":"A Schramm","year":"2015","unstructured":"Schramm\u00a0A et\u00a0al (2015) Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. J\u00a0Neural Transm 122(10):1457\u20131463","journal-title":"J. Neural. Transm."},{"issue":"3","key":"1120_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi\u00a0KD et al (2012) Satisfaction with botulinum toxin treatment: a\u00a0cross-sectional survey of patients with cervical dystonia. J\u00a0Med Econ 15(3):419\u2013423","journal-title":"J Med Econ"},{"issue":"19","key":"1120_CR16","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson\u00a0DM et\u00a0al (2016) Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurol 86(19):1818\u20131826","journal-title":"Neurol"},{"issue":"3","key":"1120_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-1331.2004.01053.x","volume":"12","author":"IM Skogseid","year":"2005","unstructured":"Skogseid\u00a0IM, Kerty\u00a0E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12(3):163\u2013170","journal-title":"Eur J Neurol"},{"key":"1120_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0733-8619(08)80003-5","volume":"26","author":"M Stacy","year":"2008","unstructured":"Stacy\u00a0M (2008) Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 26:23\u201342","journal-title":"Neurol Clin"},{"issue":"5","key":"1120_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","volume":"16","author":"D Truong","year":"2010","unstructured":"Truong\u00a0D, Global Dysport Cervical Dystonia Study Group, Global Dysport Cervical Dystonia Study Group (2010) Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Park Rel Dis 16(5):316\u2013323","journal-title":"Park Rel Dis"},{"issue":"4","key":"1120_CR20","first-page":"579","volume":"3","author":"M Weaver","year":"1997","unstructured":"Weaver\u00a0M (1997) Issues in the measurement of satisfaction with treatment. Am J Man Care 3(4):579\u2013594","journal-title":"Am J Man Care"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01120-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-021-01120-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01120-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T19:13:12Z","timestamp":1638817992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-021-01120-1"}},"subtitle":["Subgruppenanalyse von INTEREST-IN-CD-2"],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01120-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"10 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0W.\u00a0Ip erkl\u00e4rt, dass er Honorare oder Reisekostenunterst\u00fctzungen von den Firmen Merz, Allergan, Ipsen, Boston Scientific und Desitin erhalten hat. A.\u00a0Schramm erkl\u00e4rt, dass er Honorare oder Reisekostenunterst\u00fctzungen von den Firmen Ipsen, Allergan, Merz und Bayer erhalten hat. P.\u00a0Maisonobe und E.\u00a0Zaragatski sind Mitarbeiter von Ipsen Pharma. T.\u00a0Sycha erkl\u00e4rt, dass er Honorare und\/oder Reisekostenunterst\u00fctzungen von den Firmen Merz, Allergan, Ipsen, Elan, Bayer, Novartis, EVER Neuropharma, Daiichi Sankyo und Shire erhalten hat.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle Patienten gaben ihre Einverst\u00e4ndniserkl\u00e4rung zur Studienteilnahme ab. INTEREST\u00a0IN\u00a0CD\u00a0II ist eine nicht interventionelle Studie und f\u00e4llt daher nicht in den Geltungsbereich der EU-Richtlinien 2001\/20\u00a0\/\u00a0EC und EU-Richtlinie 2005\/28\u00a0\/\u00a0EC. Die Studie wurde mit Zustimmung der jeweils zust\u00e4ndigen Ethikkommission im Einklang mit dem jeweiligen nationalen Recht, den Leitlinien und Empfehlungen zur Sicherung guter epidemiologischer Praxis (GEP) sowiegem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}